Literature DB >> 23494611

Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery.

Hiroyuki Kato1, Masanobu Usui, Shuji Isaji, Takukazu Nagakawa, Keita Wada, Michiaki Unno, Akimasa Nakao, Shuichi Miyakawa, Tetsuo Ohta.   

Abstract

BACKGROUND: Optimal treatment types and prognosis for patients with borderline resectable pancreatic cancer (BRPC) remain unclear because of the lack of studies involving large series of patients.
METHODS: We retrospectively analyzed various prognostic factors for 624 BRPC (pancreatic head/body) patients treated from June 2002 to May 2007, by distributing questionnaires to member institutions of the Japanese Society of Pancreatic Surgery in 2010. BRPC was defined according to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (2009).
RESULTS: Among 624 patients, 539 (86.4 %) underwent curative-intent resection, showing an R0 resection rate of 65.9 %. The 3- and 5-year survival rates were 16.1 and 9.9 % in all patients, 22.8 and 12.5 % in the resected patients, and 4.4 and 0 % (P < 0.0001) in the unresected patients, respectively. The following factors influencing survival in all patients were selected as independent prognostic factors using multivariate analysis: major arterial involvement on imaging study; preoperative treatment; surgical resection; and postoperative chemotherapy. Among the resected cases, multivariate analysis revealed that major arterial involvement and remnant tumor status were independent prognostic factors.
CONCLUSION: BRPC included two distinct categories of tumors influencing survival: those with portal vein/superior mesenteric vein invasion alone and those with major arterial invasion, which was the most exacerbating factor in the analysis.
© 2013 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  aggressive surgical resection; borderline resectable pancreatic cancer; japanese society of pancreatic surgery

Mesh:

Year:  2013        PMID: 23494611     DOI: 10.1007/s00534-013-0595-1

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  19 in total

1.  Outcomes in patients with pancreatic cancer as a secondary malignancy: a retrospective single-institution study.

Authors:  Sojun Hoshimoto; Shoichi Hishinuma; Hirofumi Shirakawa; Moriaki Tomikawa; Iwao Ozawa; Yoshiro Ogata
Journal:  Langenbecks Arch Surg       Date:  2019-11-25       Impact factor: 3.445

Review 2.  Borderline resectable pancreatic cancer: definitions and management.

Authors:  Nicole E Lopez; Cristina Prendergast; Andrew M Lowy
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer.

Authors:  Jae Seok Bae; Jung Hoon Kim; Ijin Joo; Won Chang; Joon Koo Han
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

4.  The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future?

Authors:  John A Windsor; Savio George Barreto
Journal:  J Gastrointest Oncol       Date:  2017-02

5.  National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival.

Authors:  Yoshiaki Murakami; Sohei Satoi; Masayuki Sho; Fuyuhiko Motoi; Ippei Matsumoto; Manabu Kawai; Goro Honda; Kenichiro Uemura; Hiroaki Yanagimoto; Makoto Shinzeki; Masanao Kurata; Shoichi Kinoshita; Hiroki Yamaue; Michiaki Unno
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

6.  Synchronous arterial resection in pancreatic cancer: A case report.

Authors:  Nicolae Bacalbasa; Irina Balescu; Mihai Dimitriu; Cristian Balalau; Florentina Furtunescu; Florentina Gherghiceanu; Daniel Radavoi; Camelia Diaconu; Ovidiu Stiru; Cornel Savu; Vladislav Brasoveanu; Claudia Stoica; Ioan Cordos
Journal:  Exp Ther Med       Date:  2022-03-15       Impact factor: 2.447

7.  Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma.

Authors:  Shugo Mizuno; Shuji Isaji; Akihiro Tanemura; Masashi Kishiwada; Yasuhiro Murata; Yoshinori Azumi; Naohisa Kuriyama; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata
Journal:  J Gastrointest Surg       Date:  2014-03-25       Impact factor: 3.452

8.  Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution.

Authors:  Alejandro Recio-Boiles; Jessica Vondrak; Summana Veeravelli; James J Mancuso; Kathylynn Saboda; Denise J Roe; Irbaz Bin Riaz; Aaron J Scott; Emad Elquza; Ali McBride; Hani M Babiker
Journal:  Ann Pancreat Cancer       Date:  2020-03-09

9.  Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.

Authors:  Yoshihiro Miyasaka; Takao Ohtsuka; Susumu Eguchi; Masafumi Inomata; Kazuyoshi Nishihara; Hiroyuki Shinchi; Koji Okuda; Hideo Baba; Hiroaki Nagano; Toshiharu Ueki; Hirokazu Noshiro; Masafumi Nakamura
Journal:  Int J Surg Protoc       Date:  2021-04-26

10.  CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery.

Authors:  Liang Zhu; Xiaohua Shi; Huadan Xue; Huanwen Wu; Ge Chen; Hao Sun; Yonglan He; Zhengyu Jin; Zhiyong Liang; Zhuoli Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.